Ebola Vaccine

The recent ebola outbreak in west Africa has stressed the need for advances in research to develop a vaccine against this deadly virus. Much progress has been made in pre-clinical and clinical studies and future vaccines for the ebola virus look promising. Here is the latest research on ebola vaccines.

January 19, 2022

Heptad stereotypy, S/Q layering, and remote origin of the SARS-CoV-2 fusion core.

Virus Evolution
Chiara MarchettiFerdinando Fiumara
January 17, 2022
Review
Open Access

The role of phosphatidylserine on the membrane in immunity and blood coagulation.

Biomarker Research
Jiao WangRobert Chunhua Zhao
January 17, 2022
Open Access

Health-related quality of life among Ebola survivors in Sierra Leone: the role of socio-demographic, health-related and psycho-social factors.

Health and Quality of Life Outcomes
Peter Bai JamesEugene B Conteh
January 14, 2022

Best practices of highly infectious decedent management: Consensus recommendations from an international expert workshop.

Journal of Occupational and Environmental Hygiene
Aurora B LeJohn J Lowe
January 13, 2022
Preprint
Open Access

Systematic analysis of human antibody response to ebolavirus glycoprotein reveals high prevalence of neutralizing public clonotypes

BioRxiv : the Preprint Server for Biology
E. C. ChenJames E. Crowe
January 13, 2022
Preprint
Open Access

In vivo single-cell profiling of lncRNAs during Ebola virus infection

BioRxiv : the Preprint Server for Biology
L. SantusM. Mele
January 14, 2022
Review

Ebola Virus Disease and Current Therapeutic Strategies: A Review.

Advances in Experimental Medicine and Biology
Kalliopi Io DiakouDimitrios Vlachakis
January 11, 2022
Review
Open Access

Potential Benefits of Antiviral African Medicinal Plants in the Management of Viral Infections: Systematic Review.

Frontiers in Pharmacology
Tamirat Bekele BeressaPatrick Engeu Ogwang
January 11, 2022
Review
Open Access

Implications of RNA Viruses in the Male Reproductive Tract: An Outlook on SARS-CoV-2.

Frontiers in Microbiology
Mohammad Ishraq ZafarHonggang Li
January 11, 2022
Review
Open Access

Multipurpose Drugs Active Against Both Plasmodium spp. and Microorganisms: Potential Application for New Drug Development.

Frontiers in Cellular and Infection Microbiology
Takuro EndoTetsuya Furuya
January 8, 2022
Correction

Author Correction: Cryo-EM structure of the Ebola virus nucleoprotein-RNA complex at 3.6 Å resolution.

Nature
Yukihiko SugitaMatthias Wolf
January 8, 2022

Generating Uniformly Cross-Reactive Ebolavirus spp. Anti-nucleoprotein Nanobodies to Facilitate Forward Capable Detection Strategies.

ACS Infectious Diseases
Laura Jo Sherwood, Andrew Hayhurst
January 6, 2022
Preprint
Open Access

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a pan-Ebolavirus Immunotherapeutic

BioRxiv : the Preprint Server for Biology
E. KuangZachary A Bornholdt
January 6, 2022

Ebola virus delta peptide is an enterotoxin.

Cell Reports
Lilia I MelnikRobert F Garry
January 5, 2022

[Remdesivir for COVID-19].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Yasuhisa Fujita

Sign up to follow this feed and discover related papers.

Related Feeds

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Acute viral rhinopharyngitis

Acute viral rhinopharyngitis, also known as "common cold", is an acute, self-limiting viral infection of the upper respiratory tract involving the nose, sinuses, pharynx and larynx. Discover the latest research on acute viral rhinopharyngitis here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

© 2022 Meta ULC. All rights reserved
/feed-previews/ebola-vaccine/e7756758-7483-4783-8f77-3b5ca9ece6a4